Hikma Pharmaceuticals Given New $16.54 Price Target at JP Morgan Cazenove (HIK)
Equities researchers at JP Morgan Cazenove lifted their target price on shares of Hikma Pharmaceuticals (LON: HIK) from $12.93 (860 GBX) to $16.54 (1100 GBX) in a report issued on Monday. The firm currently has an “overweight” rating on the stock.
Hikma Pharmaceuticals opened at 930.50 on Monday. Hikma Pharmaceuticals has a 1-year low of GBX 598.50 and a 1-year high of GBX 888.00. The stock’s 50-day moving average is currently GBX 728.8. The company’s market cap is £1.823 billion.
A number of other analysts have also recently weighed in on HIK. Analysts at JPMorgan Chase reiterated an “overweight” rating on shares of Hikma Pharmaceuticals in a research note to investors on Monday. They now have a $16.54 price target on the stock. Separately, analysts at UBS AG reiterated a “sell” rating on shares of Hikma Pharmaceuticals in a research note to investors on Monday. They now have a $11.35 price target on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Hikma Pharmaceuticals in a research note to investors on Friday. They now have a $13.52 price target on the stock.
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.